BOD Australia (BDA.ASX) signs exclusive deal with iX Biopharma Ltd
While the newswire is running hot, let’s check in with BOD Australia (BDA.ASX).
Under the agreement, Bod Australia will supply iX Biopharma with a range of medicinal cannabis extracts including oils and raw materials. These extracts will be utilised by iX Biopharma to create a unique natural medicine product delivered on iX Biopharma’s proprietary WaferiX technology for use in the Company’s Phase I Clinical trials.
Singapore based iX Biopharma (IXBIO.SP) describe themselves as “an innovative late-stage specialty pharmaceutical company with expertise in drug delivery and formulation.”
The proprietary WaferiX technology of which they speak utilises a sublingual delivery mechanism to increase bio-availability. Sublingual, from the Latin for “under the tongue”, refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue.
Bit of a mouthful but you get the gist.
So,
CBD wafers Under the tongue Clinical trials coming soon.
Investors likey. The chart, please.
Nice. Some textbook setups there for anyone looking to get long.
BDA Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
